Manipulation of Cellular Processing Bodies and Their Constituents by Viruses

Asit K. Pattnaik and Phat X. Dinh

The processing bodies (PBs) are a form of cytoplasmic aggregates that house the cellular RNA decay machinery as well as many RNA-binding proteins and mRNAs. The PBs are constitutively present in eukaryotic cells and are involved in maintaining cellular homeostasis by regulating RNA metabolism, cell signaling, and survival. Virus infections result in modification of the PBs and their constituents. Many viruses induce compositionally altered PBs, while many others use specific components of the PBs for their replication. PB constituents are also known to restrict virus replication by a variety of mechanisms. Further, continuing studies in this rapidly emerging field of PB-virus interactions will undoubtedly provide important clues to the understanding of the role of PBs in cellular homeostasis as well as their role in virus infections and innate immune signaling.

Introduction

EUKARYOTIC CELLS RESPOND to virus infections or stress conditions by limiting or arresting cellular and viral protein translation through degradation of viral and cellular mRNAs, as well as by sequestering mRNAs and translation initiation factors in cytoplasmic RNP granules. Two such RNP granules, the stress granules (SGs), and the processing bodies (PBs, also known as GW bodies) (Eystathiou *et al.*, 2003; Eulalio *et al.*, 2007) have been well-characterized in the recent years. Both SGs and PBs are electron-dense, nonmembranous, and highly dynamic structures that constantly exchange RNAs and proteins with the cytoplasm, while specific marker proteins also remain static within these granules (Buchan and Parker, 2009). Over 100 mammalian genes have been identified for SG assembly, nearly 40 genes for PB assembly, and over 30 genes for coordinate SG and PB assembly (Ohn *et al.*, 2008). Mechanistically, the molecular events leading to the assembly of SGs and PBs are poorly understood but it is thought that the PB formation involves aggregation of RNA-binding proteins and mRNAs in the cytosol (Franks and Lykke-Andersen, 2008). Since these granules are nonmembranous, it is intriguing to conceptualize their nucleation, assembly and maintenance without liquid (matrix) mixing with the cytosol. However, recent studies suggest a unifying principle of compartmentalization without membranes in which a concentration-dependent liquid-liquid unmixing of mRNAs and proteins with low complexity sequence domains (regions with low amino acid diversity) may drive assembly of such granules (Kato *et al.*, 2012). Signaling through the dual specificity tyrosine-phosphorylation-regulated kinase 3 (DYRK3) and the

mechanistic target of rapamycin C1 (mTORC1) is required for the assembly of these granules (Wippich *et al.*, 2013).

The PBs are constitutively present in the cytoplasm of cells under physiological conditions (Kulkarni *et al.*, 2010) and their number and size increase upon translational arrest (Teixeira *et al.*, 2005). The PBs are involved in sequestration, storage, and/or degradation of mRNAs (Brenques *et al.*, 2005; Kulkarni *et al.*, 2010). Constituents of PBs include proteins that function in general mRNA degradation pathways, such as Xrn1, Dcp1-2, Lsm1-7, Lsm16 (Edc3), Rap55 (Lsm14A), Ge1 (Hedls, Edc4), PatL1, DDX6; proteins involved in nonsense-mediated mRNA decay (NMD) pathway; translational repressors, such as eIF4E-T, CPEB1, Lsm14A, PatL1, and DDX6; and components of the RNAi pathway, including Ago1-4, GW182, Dicer, miRNAs (Ernault-Lange *et al.*, 2012). The PBs and SGs share many mRNAs and proteins (described here as PB-SG markers) such as Ago1-4, APOBEC, BRF1, DDX3/6, eIF4E, FAST Lin28, Mex3b, PCBP1-2, Rap55, TTP, Upf1, Xrn1; however, proteins, such as Ccr4, Dcp1-2, Edc1-3, eIF4E-T, GW182, Ge1, Lsm1-7, Mex3a, PatL1, Pan2, Pop2 (described here as PB markers) are only found in the PBs (Buchan and Parker, 2009) (Fig. 1). It has been suggested that the PBs are the nucleation sites for SG formation (Kedersha *et al.*, 2005).

Alteration of PBs by Virus Replication

Although a significant body of information is available on how viruses influence the SGs and their constituents, less is known about the viral manipulation of the PBs and their constituents. Interestingly, the majority of the viruses currently

School of Veterinary Medicine and Biomedical Sciences and the Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, Nebraska.

FIG. 1. Interaction of viruses with PBs and its constituents. Cellular proteins (in rectangular box on the left side) aggregate to form PB (shown as a circle) with PB markers in blue and PB-SG markers in red. Shown are viruses that use various PB constituents to support their replication, while other viruses are inhibited by various components. HCV, WNV, DeV, Polio, and CVB3 virus infection cause redistribution of PB markers to viral replication sites near lipid droplet (yellow circles) around the ER. Some viruses inhibit aggregation of proteins (identified along the lines) into PB. Many individual PB and PB-SG components (identified with outlines within the circle) have been found to support or antagonize virus replication. SG, stress granule; PBs, processing bodies; HIV-1, human immunodeficiency virus 1; HBV, hepatitis B virus; PFV1, prototype foamy virus 1; TMV, tobacco mosaic virus; TBSV, tomato bushy stunt virus; CPV, cricket paralysis virus; WSSV, white spot syndrome virus; TCV, turnip crinkle virus; HCMV, human cytomegalovirus; DeV, dengue virus; WNV, West Nile virus; HTLV, human T-lymphotropic virus; L-A, yeast L-A double-stranded RNA virus; 20S RNA, 20S RNA narnavirus; YFV, yellow fever virus; Ty1, Ty1 retrotransposon; Ad5, adenovirus 5; BMV, brome mosaic virus; HSV-1, herpes simplex virus 1; HCV, hepatitis C virus; CVB3, Coxsackie virus B3; ER, endoplasmic reticulum; N, nucleus.

known to influence PBs are the RNA viruses, most of which are positive-stranded.

Recent studies have revealed that HCV replication leads to dispersion or alteration of PBs in cells, while virus-receptor interactions or viral protein expression have no discernible effect (Ariumi *et al.*, 2011; Perez-Vilaro *et al.*, 2012; Pager *et al.*, 2013). Interestingly, not all PBs were disrupted by HCV replication (Perez-Vilaro *et al.*, 2012; Pager *et al.*, 2013) and the number of PBs as examined by the use of PB markers Dcp1 or GW182 were similar to those in uninfected cells (Perez-Vilaro *et al.*, 2012), indicating that HCV replication alters PB composition (Perez-Vilaro *et al.*, 2012; Pager *et al.*, 2013). Similarly, in cells infected with West Nile virus (WNV) and Dengue virus, PBs are disrupted and their number declines due primarily to the recruitment of many of the PB constituents (Lsm1, GW182, DDX3/6, Xrn1) to the sites of viral replication (Emara and Brinton, 2007; Chahar *et al.*, 2012). Disruption of PBs is also seen in cells infected with poliovirus and Coxsackievirus B3 as a result of degradation of Pan3, Xrn1, and Dcp1 (Dougherty *et al.*, 2011), although other PB markers (DDX6, GW182, Edc3) were not degraded. It appears that degradation of some PB markers in these

picornavirus-infected cells may be sufficient to disrupt PBs. However, use of multiple PB markers would be necessary for a clear understanding of the role of PBs in these virus-infected cells.

Among the negative-strand RNA viruses, the influenza virus NS1 protein suppresses formation of PBs (Mok *et al.*, 2012) through interaction with Rap55, a PB constituent. This interaction is thought to be necessary for efficient viral replication through blocking the sequestration of the viral NP and the NP-associated RNAs in PBs. The PBs also appears to play important role(s) in supporting Hantavirus transcription by sequestering nucleocapsid protein-bound cellular mRNAs containing 5'-caps (Mir *et al.*, 2008). In vesicular stomatitis virus (VSV) infected cells, viral P protein interacts and colocalizes with PB-SG markers, PCBP1/2 (Dinh *et al.*, 2011). Although PB formation appears to be unaffected by VSV infection (Dinh *et al.*, 2013), further work with additional PB-specific markers would be necessary.

Less is evident about how DNA viruses affect PBs in infected cells. The number of PBs is reduced in adenovirus-infected cells as the viral E4 11K protein, through its specific interaction with DDX6, mediates redistribution of several PB

components to aggresomes (Greer *et al.*, 2011) (Fig. 1), the sites for inactivation or degradation of cellular misfolded/unwanted proteins (Kopito, 2000).

Thus, it appears that individual viruses manipulate and modify the PBs and their constituents by disparate mechanisms; however, the precise role(s) of the PBs in viral life cycle remains unclear. This is primarily due to the fact that (1) majority of these studies use PB-SG markers but draw specific conclusions only for PBs; (2) in many cases, the number of PB markers used is limited, especially when a PB protein is silenced, PB formation by that specific protein was examined, while PB formation by other authentic PB markers was not analyzed; and (3) in several studies, the role of PB markers hijacked by viruses was not investigated simultaneously with the disruption of PB. These experimental shortcomings have restricted unequivocal interpretation of the role of the PBs and/or their constituents in virus infections.

PB Constituents That Support Virus Replication

Among the PB components translocating to HCV replication sites around lipid droplets, DDX6, Ago2, Lsm1, PatL1, Ge1, and miR122 were found to be required for HCV replication as their knockdown negatively affected viral RNA replication and virus growth (Ariumi *et al.*, 2011; Berezhna *et al.*, 2011; Pager *et al.*, 2013; Thibault *et al.*, 2013). In contrast, knockdown of Rap55, another PB-associated marker, resulted in reduced PBs in the cells, but had no adverse effect on HCV replication or virus production (Perez-Vilaro *et al.*, 2012). HCV replication supporting structures formed around lipid droplets that contain hijacked PB markers appear to be distinct from the canonical PBs, suggesting that HCV replication induces the formation of compositionally altered PBs (Berezhna *et al.*, 2011; Perez-Vilaro *et al.*, 2012). It appears that HCV selectively takes advantage of several factors belonging to PB-RNAi pathway (Ago2, GW182, miR122) and PB-mRNA decay pathway (Lsm1, GW182, DDX6, Ge1, Xrn1) for replication, while other PB components, such as Rap55, Dcp1-2 do not seem to influence HCV replication. Mechanistically, how the PB constituents that translocate to lipid droplets are involved for HCV replication is not known at this time but a protective role of miR122 in antagonizing the exonuclease activity of Xrn1 in HCV RNA degradation has been recently demonstrated (Li *et al.*, 2013).

As shown in Figure 1, PB constituents support replication of many viruses in mammalian cells. PB constituents are also required for virus infections in yeast. Using *Saccharomyces cerevisiae*, Dhh1 (DDX6 homolog), Kem1 (Xrn1 homolog), Lsm1, and Pat1 (PatL1 homolog) were shown to support assembly of retrotransposition-competent virus-like particles of Ty1 (Checkley *et al.*, 2010). Brome mosaic virus (BMV) infection increases the number and size of PB foci (Beckham *et al.*, 2007) and it has been shown that BMV replication and protein expression in yeast requires Lsm1-7, Dhh1, and Pat1. Lsm1 interacts and colocalizes with viral RdRp and RNA. Lsm1-7 binds to a tRNA-like structure at the 3'-untranslated region and two internal A-rich single-stranded regions in the BMV genome to regulate viral replication and translation (Galao *et al.*, 2010).

Utilization of PB components by DNA viruses is less well characterized. HSV-1 Us11 protein was shown to interact with PatL1, a cellular kinesin light-chain-related protein (Benboud-

jema *et al.*, 2003). This interaction is presumed to be important for the intracellular movement of viral components. Hepatitis B virus (HBV), core (HBc), and surface (HBs) proteins but not HBx protein interact and colocalize with Ago2 in the ER and other subcellular compartments, while Ago2 appears to play a role in HBV life cycle (Hayes *et al.*, 2012). The Kaposi's sarcoma-associated herpesvirus SOX protein induces internal cleavage of host mRNA, which are then degraded by the 5'-3' cellular exonuclease Xrn1 (Covarrubias *et al.*, 2011).

These studies shed light into our understanding of how viruses exploit PB proteins to enhance their replication. Many components of the cellular RNAi pathway as well as miRNAs are localized into PBs and it seems that in addition to its putative roles in suppression of virus infection (Arbuthnot, 2010), multiple PB-RNAi proteins are utilized by both RNA and DNA viruses for their replication, assembly and budding.

PB Constituents That Suppress Virus Replication

PB constituents are also known to suppress replication of many viruses (Fig. 1). Prominent among these are certain members of APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypeptide like 3) family, which are incorporated into PBs and encode cytidine deaminase activity to mutate cytidine residues into uridines in nascent minus strand of retroviral reverse transcripts leading to G to A hyper-mutation in the plus-strand of viral DNA and compromise virus replication (Harris *et al.*, 2003; Bishop *et al.*, 2004). Among the seven members in APOBEC3 family, four have been shown to antagonize HIV-1 (Martin *et al.*, 2011; Imahashi *et al.*, 2012). APOBEC3F and 3G localize to PBs as well as SGs (Wichroski *et al.*, 2006; Gallois-Montbrun *et al.*, 2007) where they interact with different proteins, including the RISC protein (Ago2), PB proteins, (Dcp1 and Dcp2) and PB-SG protein (DDX6) (Kozak *et al.*, 2006). Although discrepancies exist with regard to interactions among various PB constituents and HIV-1 RNA, mRNA, and Gag proteins (Nathans *et al.*, 2009; Yu *et al.*, 2011; Bouttier *et al.*, 2012; Phalora *et al.*, 2012; Reed *et al.*, 2012), the majority of the studies show that many PB components suppress HIV-1 replication by multiple mechanisms. Similar to APOBEC3, Mov10, an RNA helicase, is incorporated into HIV-1 particles. Mov10 associates with APOBEC3, localizes to PB as a partner of Ago2 in RNAi pathway (Meister *et al.*, 2005) and inhibits HIV-1 replication (Burdick *et al.*, 2010).

Viral Countermeasures for PB Constituents

The antagonistic properties of APOBEC3 proteins on HIV-1 replication are countered by the viral vif protein (Imahashi *et al.*, 2012), which degrades APOBEC3 proteins. In human T-lymphotropic virus type 1 infection, viral tax protein inhibits NMD pathway via upregulation of Upf1 phosphorylation and accumulation of phospho-Upf1 in PBs, leading to stabilization of viral and cellular mRNAs to support virus infection (Mocquet *et al.*, 2012). Another PB constituent that is targeted by a viral component is Xrn1, the 5'-3' exonuclease, which degrades decapped mRNAs (Jones *et al.*, 2012). Genomic RNAs of positive stranded and double stranded RNA viruses serve directly as mRNA for translation and their stability is regulated by Xrn1 (and its homologs) as demonstrated for HCV, Tombusvirus, and L-A virus

(Esteban *et al.*, 2008; Jaag and Nagy, 2009; Li *et al.*, 2013). In contrast, Xrn1-mediated mRNA cleavage is not allowed to complete the degradation of viral genome RNA in cells infected with Flaviviruses (including WNV, Dengue, Kunjin, and Yellow fever virus) (Funk *et al.*, 2010; Silva *et al.*, 2010; Moon *et al.*, 2012) due to the presence of secondary and tertiary structures at the 3'-UTR of the viral genomes, resulting in the production of short subgenomic flavivirus RNA (sfRNA), which is required for viral infections (Moon *et al.*, 2012) and pathogenesis in mice (Silva *et al.*, 2010). These studies indicate that sfRNA attenuates Xrn1 activity to allow virus replication to continue unabated. In contrast, Poliovirus selectively degrades Xrn1, a step presumed to be prerequisite for subsequent disruption of PB in infected cells (Dougherty *et al.*, 2011).

Concluding Remarks

The consequences of viral interactions with cellular PBs and their constituents appear to be multifold. While some are beneficial, other interactions negatively affect virus replication, and therefore, viruses have evolved mechanisms to counter the PBs and their components. As the field of PB-virus interactions is growing rapidly, mechanistic understanding of how different viruses manipulate PBs and their constituents will likely emerge. The current knowledge of the role of PBs in virus infections is less complete primarily due to lack of studies using multiple PB-specific markers in infected cells. Thus, the real role(s) played by PBs in virus infections remain elusive. Additionally, how virus infections and subsequent cellular signaling events lead to increase in size and number of PBs in cells is poorly understood. Since PBs are intracellular granules constitutively present in normal cells and play key roles in RNA metabolism, studies examining how viruses modulate DYRK3-mTORC1 signaling in granule formation and dissolution may provide a better understanding of the form and function of this intriguing organelle in cell biology as well as in virus-host interactions. Recent identification of Rap55, a PB-associated protein, as a sensor of viral nucleic acids that activates antiviral responses in early stages of viral infections (Li *et al.*, 2012) suggests that PBs and their constituents are not only important maintaining cellular homeostasis by regulating RNA metabolism, cell signaling, and survival but they may also play key roles in innate immune signaling.

Disclosure Statement

No competing financial interests exist.

References

- Arbuthnot, P. (2010). Harnessing RNA interference for the treatment of viral infections. *Drug News Perspect* **23**, 341–350.
- Ariumi, Y., Kuroki, M., Kushima, Y., Osugi, K., Hijikata, M., Maki, M., Ikeda, M., and Kato, N. (2011). Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. *J Virol* **85**, 6882–6892.
- Beckham, C.J., Light, H.R., Nissan, T.A., Ahlquist, P., Parker, R., and Nogueira, A. (2007). Interactions between brome mosaic virus RNAs and cytoplasmic processing bodies. *J Virol* **81**, 9759–9768.
- Benboudjema, L., Mulvey, M., Gao, Y., Pimplikar, S.W., and Mohr, I. (2003). Association of the herpes simplex virus type 1 Us11 gene product with the cellular kinesin light-chain-related protein PAT1 results in the redistribution of both polypeptides. *J Virol* **77**, 9192–9203.
- Berezna, S.Y., Supekova, L., Sever, M.J., Schultz, P.G., and Deniz, A.A. (2011). Dual regulation of hepatitis C viral RNA by cellular RNAi requires partitioning of Ago2 to lipid droplets and P-bodies. *RNA* **17**, 1831–1845.
- Bishop, K.N., Holmes, R.K., Sheehy, A.M., Davidson, N.O., Cho, S.J., and Malim, M.H. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins. *Curr Biol* **14**, 1392–1396.
- Bouttier, M., Saumet, A., Peter, M., Courgnaud, V., Schmidt, U., Cazeville, C., Bertrand, E., and Lecellier, C.H. (2012). Retroviral GAG proteins recruit AGO2 on viral RNAs without affecting RNA accumulation and translation. *Nucleic Acids Res* **40**, 775–786.
- Bregues, M., Teixeira, D., and Parker, R. (2005). Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies. *Science* **310**, 486–489.
- Buchan, J.R., and Parker, R. (2009). Eukaryotic stress granules: the ins and outs of translation. *Mol Cell* **36**, 932–941.
- Burdick, R., Smith, J.L., Chaipan, C., Friew, Y., Chen, J., Venkatachari, N.J., Delviks-Frankenberry, K.A., Hu, W.S., and Pathak, V.K. (2010). P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. *J Virol* **84**, 10241–10253.
- Chahar, H.S., Chen, S., and Manjunath, N. (2012). P-body components LSM1, GW182, DDX3, DDX6 and XRN1 are recruited to WNV replication sites and positively regulate viral replication. *Virology* **436**, 1–7.
- Checkley, M.A., Nagashima, K., Lockett, S.J., Nyswaner, K.M., and Garfinkel, D.J. (2010). P-body components are required for Ty1 retrotransposition during assembly of retrotransposition-competent virus-like particles. *Mol Cell Biol* **30**, 382–398.
- Covarrubias, S., Gaglia, M.M., Kumar, G.R., Wong, W., Jackson, A.O., and Glaunsinger, B.A. (2011). Coordinated destruction of cellular messages in translation complexes by the gamma-herpesvirus host shutoff factor and the mammalian exonuclease Xrn1. *PLoS Pathog* **7**, e1002339.
- Dinh, P.X., Beura, L.K., Das, P.B., Panda, D., Das, A., and Pattnaik, A.K. (2013). Induction of stress granule-like structures in vesicular stomatitis virus-infected cells. *J Virol* **87**, 372–383.
- Dinh, P.X., Beura, L.K., Panda, D., Das, A., and Pattnaik, A.K. (2011). Antagonistic effects of cellular poly(C) binding proteins on vesicular stomatitis virus gene expression. *J Virol* **85**, 9459–9471.
- Dougherty, J.D., White, J.P., and Lloyd, R.E. (2011). Poliovirus-mediated disruption of cytoplasmic processing bodies. *J Virol* **85**, 64–75.
- Emara, M.M., and Brinton, M.A. (2007). Interaction of TIA-1/TIAR with West Nile and dengue virus products in infected cells interferes with stress granule formation and processing body assembly. *Proc Natl Acad Sci U S A* **104**, 9041–9046.
- Ernault-Lange, M., Benard, M., Kress, M., and Weil, D. (2012). P-bodies and mitochondria: which place in RNA interference? *Biochimie* **94**, 1572–1577.
- Esteban, R., Vega, L., and Fujimura, T. (2008). 20S RNA narnavirus defies the antiviral activity of SKI1/XRN1 in *Saccharomyces cerevisiae*. *J Biol Chem* **283**, 25812–25820.
- Eulalio, A., Behm-Ansmant, I., and Izaurralde, E. (2007). P bodies: at the crossroads of post-transcriptional pathways. *Nature reviews*. *Mol Cell Biol* **8**, 9–22.
- Eystathiou, T., Jakymiw, A., Chan, E.K., Seraphin, B., Cougot, N., and Fritzler, M.J. (2003). The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSM4 in cytoplasmic GW bodies. *RNA* **9**, 1171–1173.

- Franks, T.M., and Lykke-Andersen, J. (2008). The control of mRNA decapping and P-body formation. *Mol Cell* **32**, 605–615.
- Funk, A., Truong, K., Nagasaki, T., Torres, S., Floden, N., Balmori Melian, E., Edmonds, J., Dong, H., Shi, P.Y., and Khromykh, A.A. (2010). RNA structures required for production of subgenomic flavivirus RNA. *J Virol* **84**, 11407–11417.
- Galao, R.P., Chari, A., Alves-Rodrigues, I., Lobao, D., Mas, A., Kambach, C., Fischer, U., and Diez, J. (2010). LSM1-7 complexes bind to specific sites in viral RNA genomes and regulate their translation and replication. *RNA* **16**, 817–827.
- Gallois-Montbrun, S., Kramer, B., Swanson, C.M., Byers, H., Lynham, S., Ward, M., and Malim, M.H. (2007). Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. *J Virol* **81**, 2165–2178.
- Greer, A.E., Hearing, P., and Ketner, G. (2011). The adenovirus E4 11 k protein binds and relocalizes the cytoplasmic P-body component Ddx6 to aggresomes. *Virology* **417**, 161–168.
- Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K., Watt, I.N., Neuberger, M.S., and Malim, M.H. (2003). DNA deamination mediates innate immunity to retroviral infection. *Cell* **113**, 803–809.
- Hayes, C.N., Akamatsu, S., Tsuge, M., Miki, D., Akiyama, R., Abe, H., Ochi, H., Hiraga, N., Imamura, M., Takahashi, S., Aikata, H., Kawaoka, T., Kawakami, Y., Ohishi, W., and Chayama, K. (2012). Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle. *PLoS One* **7**, e47490.
- Imahashi, M., Nakashima, M., and Iwatani, Y. (2012). Antiviral mechanism and biochemical basis of the human APOBEC3 family. *Front Microbiol* **3**, 250.
- Jaag, H.M., and Nagy, P.D. (2009). Silencing of *Nicotiana benthamiana* Xn4p exoribonuclease promotes tombusvirus RNA accumulation and recombination. *Virology* **386**, 344–352.
- Jones, C.I., Zabolotskaya, M.V., and Newbury, S.F. (2012). The 5'→3' exoribonuclease XRN1/Pacman and its functions in cellular processes and development. *Wiley interdisciplinary reviews. RNA* **3**, 455–468.
- Kato, M., Han, T.W., Xie, S., Shi, K., Du, X., Wu, L.C., Mirzaei, H., Goldsmith, E.J., Longgood, J., Pei, J., Grishin, N.V., Frantz, D.E., Schneider, J.W., Chen, S., Li, L., Sawaya, M.R., Eisenberg, D., Tycko, R., and McKnight, S.L. (2012). Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. *Cell* **149**, 753–767.
- Kedersha, N., Stoecklin, G., Ayodele, M., Yacono, P., Lykke-Andersen, J., Fritzler, M.J., Scheuner, D., Kaufman, R.J., Golan, D.E., and Anderson, P. (2005). Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. *J Cell Biol* **169**, 871–884.
- Kopito, R.R. (2000). Aggresomes, inclusion bodies and protein aggregation. *Trends Cell Biol* **10**, 524–530.
- Kozak, S.L., Marin, M., Rose, K.M., Bystrom, C., and Kabat, D. (2006). The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polyosomes and stress granules. *J Biol Chem* **281**, 29105–29119.
- Kulkarni, M., Ozgur, S., and Stoecklin, G. (2010). On track with P-bodies. *Biochem Soc Trans* **38**, 242–251.
- Li, Y., Chen, R., Zhou, Q., Xu, Z., Li, C., Wang, S., Mao, A., Zhang, X., He, W., and Shu, H.B. (2012). LSM14A is a processing body-associated sensor of viral nucleic acids that initiates cellular antiviral response in the early phase of viral infection. *Proc Natl Acad Sci U S A* **109**, 11770–11775.
- Li, Y., Masaki, T., Yamane, D., McGivern, D.R., and Lemon, S.M. (2013). Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication. *Proc Natl Acad Sci U S A* **110**, 1881–1886.
- Martin, K.L., Johnson, M., and D'Aquila, R.T. (2011). APOBEC3G complexes decrease human immunodeficiency virus type 1 production. *J Virol* **85**, 9314–9326.
- Meister, G., Landthaler, M., Peters, L., Chen, P.Y., Urlaub, H., Luhrmann, R., and Tuschl, T. (2005). Identification of novel argonaute-associated proteins. *Curr Biol* **15**, 2149–2155.
- Mir, M.A., Duran, W.A., Hjelle, B.L., Ye, C., and Panganiban, A.T. (2008). Storage of cellular 5' mRNA caps in P bodies for viral cap-snatching. *Proc Natl Acad Sci U S A* **105**, 19294–19299.
- Mocquet, V., Neusiedler, J., Rende, F., Cluet, D., Robin, J.P., Terme, J.M., Duc Dodon, M., Wittmann, J., Morris, C., Le Hir, H., Ciminale, V., and Jalinot, P. (2012). The human T-lymphotropic virus type 1 tax protein inhibits nonsense-mediated mRNA decay by interacting with INT6/EIF3E and UPF1. *J Virol* **86**, 7530–7543.
- Mok, B.W., Song, W., Wang, P., Tai, H., Chen, Y., Zheng, M., Wen, X., Lau, S.Y., Wu, W.L., Matsumoto, K., Yuen, K.Y., and Chen, H. (2012). The NS1 protein of influenza A virus interacts with cellular processing bodies and stress granules through RNA-associated protein 55 (RAP55) during virus infection. *J Virol* **86**, 12695–12707.
- Moon, S.L., Anderson, J.R., Kumagai, Y., Wilusz, C.J., Akira, S., Khromykh, A.A., and Wilusz, J. (2012). A noncoding RNA produced by arthropod-borne flaviviruses inhibits the cellular exoribonuclease XRN1 and alters host mRNA stability. *RNA* **18**, 2029–2040.
- Nathans, R., Chu, C.Y., Serquina, A.K., Lu, C.C., Cao, H., and Rana, T.M. (2009). Cellular microRNA and P bodies modulate host-HIV-1 interactions. *Mol Cell* **34**, 696–709.
- Ohn, T., Kedersha, N., Hickman, T., Tisdale, S., and Anderson, P. (2008). A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly. *Nat Cell Biol* **10**, 1224–1231.
- Pager, C.T., Schutz, S., Abraham, T.M., Luo, G., and Sarnow, P. (2013). Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrichment of stress granules. *Virology* **435**, 472–484.
- Perez-Vilaro, G., Scheller, N., Saludes, V., and Diez, J. (2012). Hepatitis C virus infection alters P-body composition but is independent of P-body granules. *J Virol* **86**, 8740–8749.
- Phalora, P.K., Sherer, N.M., Wolinsky, S.M., Swanson, C.M., and Malim, M.H. (2012). HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. *J Virol* **86**, 11712–11724.
- Reed, J.C., Molter, B., Geary, C.D., McNevin, J., McElrath, J., Giri, S., Klein, K.C., and Lingappa, J.R. (2012). HIV-1 Gag coopts a cellular complex containing DDX6, a helicase that facilitates capsid assembly. *J Cell Biol* **198**, 439–456.
- Silva, P.A., Pereira, C.F., Dalebout, T.J., Spaan, W.J., and Bredenbeek, P.J. (2010). An RNA pseudoknot is required for production of yellow fever virus subgenomic RNA by the host nuclease XRN1. *J Virol* **84**, 11395–11406.
- Teixeira, D., Sheth, U., Valencia-Sanchez, M.A., Brengues, M., and Parker, R. (2005). Processing bodies require RNA for assembly and contain nontranslating mRNAs. *RNA* **11**, 371–382.
- Thibault, P.A., Huys, A., Dhillon, P., and Wilson, J.A. (2013). MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells. *Virology* **436**, 179–190.
- Wichroski, M.J., Robb, G.B., and Rana, T.M. (2006). Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. *PLoS Pathog* **2**, e41.

- Wippich, F., Bodenmiller, B., Trajkovska, M.G., Wanka, S., Aebersold, R., and Pelkmans, L. (2013). Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. *Cell* **152**, 791–805.
- Yu, S.F., Lujan, P., Jackson, D.L., Emerman, M., and Linial, M.L. (2011). The DEAD-box RNA helicase DDX6 is required for efficient encapsidation of a retroviral genome. *PLoS Pathog* **7**, e1002303.

Address correspondence to
Asit K. Pattnaik, PhD
School of Veterinary Medicine and Biomedical Sciences
Nebraska Center for Virology
University of Nebraska-Lincoln
109 Morrison Life Science Research Center
4240 Fair Street
Lincoln, NE 68583-0900
E-mail: apattnaik2@unl.edu

Received for publication March 29, 2013; accepted March 29, 2013.